SPRY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SPRY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-04-30), ARS Pharmaceuticals's share price is $13.92. ARS Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.05. Hence, ARS Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is 262.64.
The historical rank and industry rank for ARS Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 5 years, ARS Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 280.75. The lowest was 197.74. And the median was 234.44.
ARS Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2024 was $0.35. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.05.
The historical data trend for ARS Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals Annual Data | |||||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||
Price-to-Free-Cash-Flow | - | - | - | - | 83.07 |
ARS Pharmaceuticals Quarterly Data | ||||||||||||||
Dec20 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | 83.07 |
For the Biotechnology subindustry, ARS Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where ARS Pharmaceuticals's Price-to-Free-Cash-Flow falls into.
ARS Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 13.92 | / | 0.053 | |
= | 262.64 |
ARS Pharmaceuticals's Share Price of today is $13.92.
ARS Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
ARS Pharmaceuticals (NAS:SPRY) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of ARS Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Laura Shawver | director, officer: Chief Executive Officer | 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Eric Karas | officer: Chief Commercial Officer | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
Richard E Lowenthal | director, 10 percent owner, officer: President and CEO | 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Sarina Tanimoto | 10 percent owner, officer: Chief Medical Officer | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
Justin Chakma | officer: Chief Business Officer | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
Brian Dorsey | officer: Chief Operating Officer | C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130 |
James E Flynn | director, 10 percent owner, other: Director by deputization | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Kathleen D. Scott | officer: Chief Financial Officer | C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Peter A. Thompson | director | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Ra Capital Healthcare Fund Lp | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Alexander A Fitzpatrick | officer: Chief Legal Officer | 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121 |
Orbimed Capital Gp Vi Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Rajeev Dadoo | director | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
Michael Kelly | director | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
From GuruFocus
By GuruFocus News • 03-21-2025
By GuruFocus News • 03-21-2025
By GuruFocus News • 02-22-2025
By Marketwired • 02-21-2025
By GuruFocus News • 12-19-2024
By Marketwired • 12-19-2024
By Marketwired • 01-06-2025
By Marketwired • 02-05-2025
By GuruFocus News • 01-08-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.